RPL13AP17

Across TCGA pan-cancer cohorts, RPL13AP17 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of RPL13AP17’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where RPL13AP17 RNA is repressed in tumor relative to normal tissue. In most cancer types RPL13AP17 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

LUAD, LUSC, and KIRC are the cancer types where RPL13AP17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPL13AP17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Male	III,IV	−3.755	<.001	9	view →
LUSC	All	III,IV	−3.636	<.001	9	view →
KIRC	All	III,IV	−0.012	.002	8	view →
KICH	All	All	+1.264	<.001	5	view →
ESCA	All	All	−0.085	.033	1	view →
THCA	All	All	−0.008	.028	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

RPL13AP17–LUAD

Open the LUAD breakdown →